A Look at Global Inflation and its Causes


Image Credit: Viv Lynch (Flickr)


Inflation is Spiking Around the World – Not Just in the United States

The 9.1% increase in U.S. consumer prices in the 12 months ending in June 2022, the highest in four decades, has prompted many sobering headlines.

Meanwhile, annual inflation in Germany and the U.K. – countries with comparable economies – ran nearly as high: 7.5% and 8.2%, respectively, for the 12 months ending in June 2022. In Spain, inflation has hit 10%.

It might seem like U.S. policies brought on this predicament, but economists like me doubt it because inflation is spiking everywhere, with few exceptions. Rates averaged 9.65% in the 38 largely wealthy countries that belong to the Organization for Economic Cooperation and Development through May 2022.

What revved up those price increases starting in early 2021?

Scarcity Put Pressure on Prices Everywhere

When the COVID-19 pandemic began, demand for computers and other high-tech goods soared as many people switched from working in offices to clocking in at home.

Computer chip manufacturers struggled to keep up, leading to chip shortages and higher prices for a dizzying array of devices and machines requiring them, including refrigerators, cars and smartphones.

It’s not just chips. Many of the goods Americans consume, such as cars, televisions and prescription drugs, are imported from all corners of the world.

This article was republished with
permission from The Conversation, a news site dedicated to sharing ideas from
academic experts. It was written by and represents the research-based opinions
of Christopher Decker, Professor of Economics, University of Nebraska Omaha.

Supply Chain Strains

On top of problems tied to supply and demand changes, there have been major disruptions to how goods move to manufacturers and then onto consumers along what’s known as the supply chain.

Freight disruption, whether by ship, train or truck, has interfered with the delivery of all sorts of goods since 2020. That’s caused the cost of shipping goods to rise sharply.

These massive shipping disruptions have exposed the disadvantages of the popular just-in-time practice for managing inventory.

By keeping as little of the materials needed to make their products on hand, companies become more vulnerable to shortages and transportation snafus. And when manufacturers are unable to make their products quickly, shortages occur and prices surge.

This approach, especially when it involves the reliance on far-flung suppliers, has left businesses much more susceptible to market shocks.

 

Labor Complications

The beginning of the pandemic also sent shock waves through labor markets with lasting effects.

Many businesses either fired or furloughed large numbers of workers in 2020. When governments began to relax restrictions related to the pandemic, many employers found that significant numbers of their former workers were unwilling to return to work.

Whether those workers had chosen to retire early, seek new jobs offering a better work-life balance or become disabled, the results were the same: labor shortages that required higher wages to recruit replacements and retain other employees.

Again, all of these dynamics are occurring globally, not just in the U.S.

War in Ukraine compounded these woes

Russia’s war on Ukraine, which began officially on Feb. 24, 2022, has also exacerbated inflation by interfering with the global supply of fuels and grains.

The conflict’s effects are reverberating around the globe and fueling inflation.

Russia is the world’s second-largest exporter of crude oil. Sanctions against Russian imports, combined with Russia halting oil shipments to European countries in retaliation, has led to disruptions in the global oil market.

As Europe buys more oil from the Middle East, demand for oil from that region increases, prompting price increases. Crude prices jumped from $101 per barrel in late February 2022, to $123 a month later. Prices stayed high for several months but by late July were around $100 a barrel again.

Food prices have increased substantially in the U.S. and elsewhere, partly due to this conflict. Ukraine possesses some of the most fertile soil in the world and is the third-largest exporter of corn.

Russia’s destruction of Ukrainian crops and its blockade of Ukrainian exports have led to significant price increases worldwide for agricultural commodities.


How Will the World Respond?

Support for globalization and international trade has waned in recent years. Given supply chain disruptions and the war in Ukraine fueling inflation, this trend will likely continue.

However, as an economist, I believe the benefits of free and open trade still outweigh current challenges.

In my view, there isn’t anything fundamentally wrong with the globalization that cannot be fixed. But, like quelling inflation and alleviating supply chain bottlenecks, it will take time.


Suggested Content



Fewer Quitters and Fewer Job Openings Suggest a Move Toward Normalcy



What Might be in a Portfolio Allocated for a Republican Majority in the House?





Useful Information on Where CPI Numbers Come From



Powell is Told by President that He is the Face of Inflation

Stay up to date. Follow us:

 

Uranium Investments and The Inflation Reduction Act



Image Credit: Johannes Plenio (Pexels)


Uranium is Reacting to Increasing Demand in the U.S. with Increased Support from Washington

The Senate approved Inflation Reduction Act (IRA) is yet another nod to nuclear energy. As the world is coming around to the idea that a significant, non-weather-dependent energy source is needed, if there is to be a successful transition away from fossil fuels, nuclear, more specifically, uranium fueled power, continues to get the nod from the U.S. Department of Energy (DOE), lawmakers in Washington, green energy groups, and even from countries like Japan and Germany. 

This IRA bill that just passed in the Senate is headed to the House with almost $400 billion in energy security and climate-related programs over the next ten years. It is expected to easily pass without much renegotiation between the two branches of Congress. Below are some specifics on how it will impact the nuclear energy industry and, therefore, uranium investments. 

 

Enriched Tax Credits for Nuclear Energy

There is a provision that improves upon the Zero-Emissions Nuclear Production law, which is a Power Tax Credit specific for nuclear energy producers. It is in the form of a scaled credit based on plant revenue and applies to existing power plants. The program now includes nuclear and would begin in 2024 and end in 2032; it will offer 5x the benefit if labor requirements are adhered to. The 2032 deadline is an extension of the original plan, which was included in Build Back Better.

The IRA provides for a technology-neutral clean energy production credit of 0.3 cents * kWh base rate for ten years starting in 2025. New, to the program is that energy producers (including coal) will receive a 10% credit in addition to any clean energy credit. This benefit does not look at the technology that is producing the energy.

 

High-Assay Low Enrichment Uranium (HALEU)

The version that passed the Senate also includes $700 million for HALEU, which is the fuel expected to be used in the next generation of reactors. This is interesting in that HALEU production is limited to Russia.

The HALEU funding is broken down into three categories and references the Energy Act of 2020:

  • $100M: Licensing and regulation of facilities and transportation packages.
  • $500M: Acquiring or providing HALEU from a stockpile of uranium to produce HALEU, estimating the quantity of HALEU necessary for domestic, commercial use, and developing a consortium to support the availability of HALEU for civilian use.
  • $100M: Support the availability of HALEU for civilian domestic research, development, demonstration, and commercial.


DOE Loans

The bill also includes $250 billion for DOE loans. The loans will help provide funding to smooth the road toward building tomorrow’s carbon-free technology currently in development.

 

Related Investments

There are many non-energy generating U.S. companies involved in the various areas of providing nuclear fuel and even storing spent fuel. Additionally, there is a futures market and ETFs that either work to mimic the price changes in U308 or own uranium outright and store and provide valuation on the trust.


Source: Pennsylvania
State University Radiation Science and Engineering Center (Public Domain)

The chart below is provided as an example of how companies involved in producing uranium, uranium futures, and the ETF that owns the mineral all trade in relation to each other (three-month period).

Energy Fuels (UUUU) is the largest uranium producer in the U.S. and holds more production capacity and uranium resources than any other U.S. producer. A new research report update on Energy Fuels by Noble Capital Markets was released today (August 8). Read it here.


Source: Koyfin

enCore Energy Corp. (ENCUF) is focused on becoming a domestic (USA) uranium producer. It has significant existing resources in the southwest United States and licensed uranium production facilities in Texas; encore holds the largest uranium position in the Grants Mineral Belt and licensed processing capacity to respond quickly to market opportunities. Discover more here.

Peninsula Energy Ltd (PENMF) is a uranium mining and development company. Projects include Lance ISR Uranium Projects located on the north-east flank of the Powder River Basin in Wyoming and Karoo Uranium Projects in South Africa. It has three reportable operating segments, Lance uranium projects, Wyoming USA; Karoo uranium projects, South Africa; and Corporate. More data on Peninsula Energy is available here, and in the video link below.


Take Away

The provisions in the Inflation Reduction Bill, which seems sure to pass the House and be signed into law, would seem to create a tailwind worth several hundred billion to the industry. It also serves as a glowing nod toward nuclear as one important piece to meeting reduced carbon emissions goals.

The IRA bill gives current investors in the related nuclear power and uranium industries a reason to be more bullish and newer investors a reason to react to the possibility of adding stocks of producers, futures contracts, or uranium itself into their portfolios.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Energy and Global Fundamentals Make a Good Case for Owning Western Uranium Stocks



Can You Invest in Uranium Directly?




Peninsula Energy (PENMF) NobleCon18 – Presentation Replay



Energy Fuels (UUUU) NobleCon18 – Presentation Replay

Sources

 

https://www.eia.gov/energyexplained/nuclear/the-nuclear-fuel-cycle.php

https://www.eia.gov/todayinenergy/detail.php?id=51978

https://thebreakthrough.org/articles/advancing-nuclear-energy-report

https://www.whitehouse.gov/wp-content/uploads/2022/08/SAP-H.R.-5376.pdf


Stay up to date. Follow us:

 

Release – Aurania Provides Update on Geological Mapping Program



Aurania Provides Update on Geological Mapping Program

Research, News, and Market Data on Aurania Resources

Toronto, Ontario, August 8, 2022 – Aurania Resources Ltd. (TSXV:
ARU; OTCQB: AUIAF; Frankfurt: 20Q) (“Aurania” or the “Company”) 
is pleased to report that, under the guidance of Senior Technical Advisor, Dr. Steve Garwin, detailed geological mapping at its Tatasham target is progressing and is expected to be completed in the coming weeks. The second phase of mapping at the Company’s Awacha target is planned to start by the end of August.

The purpose of this field work is to apply the Anaconda mapping method to define the drill targets at Tatasham and Awacha. The Anaconda method was developed in the 60’s and 70’s by Anaconda Copper and has led to the discovery and resource expansion of several porphyry copper-gold deposits including the Apala deposit in Ecuador and Cortadera in Chile.  To learn more about the importance of geological mapping and the Anaconda technique, click
here to view a video with Steve Garwin recorded during the GeoHug webinar
series July 2021.

The Company also announces that its Chairman, President and Chief Executive Officer, Dr. Keith Barron (the “Lender”) completed a loan of C$1,000,000 to the Company. The loan is unsecured, bears interest at 2% per annum and matures upon notice of twelve months and one day from the Lender.  The loan will help fund the Company’s working capital and ongoing exploration activities.

Dr. Keith Barron is a related party of the Company by virtue of the fact that he is the Chairman, the President and Chief Executive Officer, a promoter and a principal shareholder of the Company, and as a result, each of the Loan constitutes a “related party transaction” for the purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying upon an exemption from the formal valuation and minority shareholder approval requirements under MI 61-101 in respect of the Related Party Transactions, in reliance on Sections 5.5(a) and 5.7(1) of MI 61-101, respectively, as the fair market value of the Related Party Transaction, collectively, does not exceed 25% of the Company’s market capitalization, as determined in accordance with MI 61-101. The Company did not file a material change report related to the Loan more than 21 days before the expected closing of the Loan as required by MI 61-101, as the Company required the funds from closing on an expedited basis for sound business reasons.

The Loan and the Insider Participation were approved by the members of the board of directors of the Company who are independent for purposes of the Related Party Transactions, being all directors other than Dr. Barron. No special committee was established in connection with the Loan and the Insider Participation, and no materially contrary view or abstention was expressed or made by any director of the Company in relation thereto.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at 
www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at  
https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir

VP Investor Relations

Aurania Resources Ltd.

(416) 367-3200

carolyn.muir@aurania.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.


Release – Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344



Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Research, News, and Market Data on Cocrystal Pharma

BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a subsidiary of London-based Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organization (CRO), to conduct a Phase 2a clinical trial with the Company’s novel, broad-spectrum, orally administered antiviral candidate CC-42344. This candidate represents a new class of investigational medicine designed to directly inhibit replication of the virus for the treatment of pandemic and seasonal influenza A.

“We are highly encouraged by the Phase 1 healthy volunteer trial results received so far and are committed to rapidly advancing this program into a human challenge Phase 2a trial in influenza A-infected subjects,” said Sam Lee, Ph.D., Cocrystal’s President and co-interim CEO. “The fact that influenza virus is constantly mutating against existing influenza antiviral drugs elevates an urgent need for effective antiviral therapeutics. CC-42344 is a broad-spectrum oral PB2 inhibitor that is highly active against drug-resistant influenza A strains. Further clinical development of CC-42344 offers an opportunity to address the need. Open Orphan is a world leader in conducting human challenge clinical trials with antiviral drug candidates, making it an ideal partner for conducting our Phase 2a trial.”

The single-center, double-blind, placebo-controlled Phase 2a human challenge trial is designed to evaluate safety, viral and clinical measures of orally administered 
CC-42344 to subjects challenged with influenza A. The trial is expected to be initiated in the second half of 2023, pending approval from the United Kingdom Medicines and Healthcare Products Regulatory Agency. This study will be conducted at hVIVO’s state-of-the-art facility in the United Kingdom.

Yamin “Mo” Khan, Open Orphan CEO, said, “We are pleased to be working with Cocrystal to evaluate its promising antiviral drug candidate for influenza A. A human challenge trial is an excellent option for Cocrystal, as it can rapidly provide efficacy data at a lower cost than traditional field trials.”

Cocrystal is conducting a Phase 1 study with CC-42344 in healthy subjects in Australia. The Company recently announced pharmacokinetic (PK) data supporting once-daily dosing from the single-ascending dose portion of this study. Enrollment in the multiple-ascending dose portion of the Phase 1 trial is ongoing, with full trial results expected in 2022.

About CC-42344 and
Influenza

CC-42344 is an oral PB2 inhibitor that blocks an essential step of viral replication. CC-42344 was discovered using Cocrystal’s proprietary structure-based drug discovery platform technology. It is specifically designed to be effective against all significant pandemic and seasonal influenza A strains and to have a high barrier to resistance due to the way the virus’ replication machinery is targeted. 
CC-42344 targets the influenza polymerase, an essential replication enzyme with several highly essential regions common to multiple influenza strains, including pandemic strains. In
vitro 
testing showed CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu® and Xofluza®, while also demonstrating favorable pharmacokinetic and safety profiles.

The global influenza therapeutics market is projected to reach $9.5 billion by 2027, from $6.6 billion in 2020, growing at a 4.8% CAGR between 2021 and 2027, according to a report published by Precision Reports in June 2022.

About hVIVO and
Open Orphan plc

hVIVO, a subsidiary of Open Orphan plc, is a rapidly growing specialist contract research organization (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and longstanding client base of biopharma companies.

About Cocrystal
Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cocrystal Pharma Cautionary
Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our collaboration with hVIVO to conduct a Phase 2a clinical trial for CC-42344 and the anticipated timeline for the study, the potential design and efficacy of CC-42344, and the demand for products designed to treat influenza and opportunities presented thereby. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the availability of federal government funding and budgetary issues that may arise, the risks and uncertainties arising from any future impact of the COVID-19 pandemic including in Australia, the Russian invasion of Ukraine, and/or inflation and Federal Reserve interest rate increases in response thereto on the global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs such as obtaining the requisite regulatory approvals including from the United Kingdom Medicines and Healthcare Products Regulatory Agency, the ability of the CRO to recruit patients into clinical trials, and the results of the studies for CC-42344. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100

jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378

Jabraham@jqapartners.com

# # #


Primary Logo

Source: Cocrystal Pharma, Inc.

Released August 8,
2022

 


Release – Kratos Receives $20 Million Unmanned Aerial Drone System Production Contract



Kratos Receives $20 Million Unmanned Aerial Drone System Production Contract

Research, News, and Market Data on Kratos Defense & Security Solutions


SAN DIEGO, 
Aug. 08, 2022 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has received an approximate 
$20 million production contract for high performance, jet powered, unmanned aerial target drone systems. Kratos is an industry leader in the development, design and fielding of affordable, high-performance jet powered unmanned aerial drone systems. The unmanned aerial drone systems produced under this contract award will be manufactured in a Kratos production facility. Due to competitive, security-related, and other considerations, no additional information will be provided related to this award.

Steve Fendley, President of Kratos Unmanned Systems Division, said, “We believe that this contract award is representative of Kratos’ industry leading position for certain of the highest performance and most capable jet drone aircraft flying in the world today. Kratos today has multiple active production lines producing approximately 150 target and tactical jet drone aircraft annually, and this new target drone production contract award is a key element of our future expected growth trajectory.”

About Kratos
Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to 
www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 26, 2021, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact: Yolanda White 858-812-7302 Direct

Investor Information:
877-934-4687

investor@kratosdefense.com

 


Release – 1-800-FLOWERS.COM, Inc. to Release Results for its Fiscal 2022 Fourth Quarter and Full Year on Thursday, September 1, 2022



1-800-FLOWERS.COM, Inc. to Release Results for its Fiscal 2022 Fourth Quarter and Full Year on Thursday, September 1, 2022

Research, News, and Market Data on 1-800-FLOWERS.COM

Aug 08, 2022

JERICHO, N.Y.–(BUSINESS WIRE)– 1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS),a leading provider of gifts designed to help inspire customers to give more, connect more, and build more and better relationships, today announced that the Company will release financial results for its fiscal 2022 fourth quarter and full year (ended 7/3/22) on Thursday, September 1, 2022. The press release will be issued prior to market opening and will be followed by a conference call with members of senior management at 8:00 a.m. (ET).

 

The conference call will be available via live webcast from the Investor Relations section of the Company’s website at 1800flowersinc.com. A recording of the call will be posted on the website within two hours of the call’s completion. A telephonic replay of the call can be accessed beginning at 2:00 p.m. (ET) on September 1, 2022, through September 8, 2022, at: (US) 1-877-344-7529; (
Canada) 855-669-9658; (International) 1-412-317-0088; enter conference ID: #4688547. If you have any questions regarding the above information, please call the Investor Relations office at (516) 237-6131.

 

Special Note Regarding Forward-Looking Statements:
Some of the statements contained in the Company’s scheduled Thursday, September 1, 2022, press release and conference call regarding its results for its fiscal 2022 fourth quarter and full year (ended 7/3/22), other than statements of historical fact, may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. For a more detailed description of these and other risk factors, please refer to the Company’s SEC filings including its Annual Reports and Forms 10K and 10Q available at the Investor Relations section of the Company’s website at 1800flowersinc.com. The Company expressly disclaims any intent or obligation to update any of the forward-looking statements made in the scheduled conference call and any recordings thereof, or in any of its SEC filings, except as may be otherwise stated by the Company.

 

About 1-800-FLOWERS.COM,
Inc.

1-800-FLOWERS.COM, Inc. is a leading provider of gifts designed to help inspire customers to give more, connect more, and build more and better relationships. The Company’s e-commerce business platform features an all-star family of brands, including: 1-800-Flowers.com®, 1-800-Baskets.com®, Cheryl’s Cookies®, Harry & David®, PersonalizationMall.com®, Shari’s Berries®, FruitBouquets.com®, Moose Munch®, The Popcorn Factory®, Wolferman’s Bakery®, Vital Choice®, Stock Yards® and Simply Chocolate®. Through the Celebrations Passport® loyalty program, which provides members with free standard shipping and no service charge across our portfolio of brands, 1-800-FLOWERS.COM, Inc. strives to deepen relationships with customers. The Company also operates BloomNet®, an international floral and gift industry service provider offering a broad-range of products and services designed to help members grow their businesses profitably; Napco?, a resource for floral gifts and seasonal décor; DesignPac Gifts, LLC, a manufacturer of gift baskets and towers; and Alice’s Table®, a lifestyle business offering fully digital livestreaming floral, culinary and other experiences to guests across the country. 1-800-FLOWERS.COM, Inc. was recognized among the top 5 on the National Retail Federation’s 2021 Hot 25 Retailers list, which ranks the nation’s fastest-growing retail companies, and was named to the Fortune 1000 list in 2022. Shares in 1-800-FLOWERS.COM, Inc. are traded on the NASDAQ Global Select Market, ticker symbol: FLWS. For more information, visit 1800flowersinc.com or follow @1800FLOWERSInc on Twitter.

 

FLWS-COMP
FLWS-FN

Investor Contact:

Joseph D. Pititto

(516) 237-6131

invest@1800flowers.com

Media Contact:

Kathleen Waugh

(516) 237-6028

kwaugh@1800flowers.com

Source: 1-800-FLOWERS.COM, Inc

 


Release – Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights



Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Research, News, and Market Data on Tonix Pharmaceuticals

Phase 1 Study
of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and
Smallpox, Expected to Initiate in First Half 2023 in Kenya; the U.S. has
Declared Monkeypox a Public Health Emergency

U.S. National Institute of Drug
Abuse (NIDA) Grant Awarded for the Development of TNX-1300 for Cocaine
Intoxication; Phase 2 Study of TNX-1300 Expected to Initiate in Fourth Quarter
2022

Advanced Development Center in
Dartmouth, Mass. is Open and Expected to Imminently Conduct Process Development
and Clinical Trial Manufacturing of Live-Virus Vaccines

Cash and Cash Equivalents
Totaled Approximately $145 Million at June 30, 2022

CHATHAM, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2022, and provided an overview of recent operational highlights.

“The rapidly expanding outbreaks of monkeypox in the U.S. and approximately 80 other countries outside of Africa have brought attention to our work on a novel monkeypox vaccine, TNX-801, which has already been shown to protect non-human primates against a challenge with lethal doses of monkeypox. The U.S. has declared monkeypox a public health emergency. In addition, we are excited by the many opportunities ahead for our pipeline of CNS, rare disease, immunology and infectious disease product candidates,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “We are on track to have four CNS programs in the clinic by the end of 2022, including our most advanced program, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, which is in mid-Phase 3 development, Phase 2 studies of TNX-102 SL for Long COVID and PTSD and a Phase 2 study of TNX-1300 for cocaine intoxication.”

Recent
Highlights—Key Product Candidates*

Infectious
Disease Pipeline

TNX-801 (live
horsepox virus vaccine for percutaneous administration): vaccine against
smallpox and monkeypox designed as a single-administration vaccine to elicit T
cell immunity

  • In July 2022, Tonix announced a collaboration with the Kenya Medical Research Institute (KEMRI) to plan, seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop TNX-801 as a vaccine to protect against monkeypox and smallpox. The study is expected to start in the first half of 2023.
  • Tonix presented data from a research collaboration with The University of Alberta in a poster presentation at the 4th Symposium of the Canadian Society for Virology. The poster titled, “Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox,” describes data from animals vaccinated with TNX-801 to protect against monkeypox. The poster presentation reports that all animals (n=8) vaccinated with TNX-801 were fully protected with sterilizing immunity from a challenge with intra-tracheal monkeypox. The vaccinations with TNX-801 were well tolerated. Synthetic horsepox virus is the basis for the Company’s TNX-801 vaccine in development to protect against monkeypox and smallpox and for the Company’s Recombinant Pox Virus (RPV) platform to protect against other pathogens, including SARS-CoV-2.
  • Tonix announced the issuance of U.S. Patent for TNX-801 smallpox and monkeypox vaccine and Recombinant Pox Virus (RPV) platform technology. This patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments.

TNX-1850 (live
virus vaccine based on Tonix’s recombinant pox virus vector): COVID-19 vaccine
designed as single-administration vaccine to elicit T cell immunity

  • Tonix announced the issuance of U.S. Patent for TNX-801 smallpox and monkeypox vaccine and Recombinant Pox Virus (RPV) platform technology (TNX-1850). This patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments.

TNX-2300: Live
virus vaccine based on a bovine parainfluenza virus vector to protect against
COVID-19

  • In April 2022, Tonix extended a sponsored research agreement with Kansas State University to develop a vaccine candidate, TNX-2300, for the prevention of COVID-19 that utilizes a novel live virus vaccine vector platform based on bovine parainfluenza virus. The efficacy of co-expression of the CD40-ligand, also known as CD154, to stimulate T cell immunity will also be tested.
  • Attenuated bovine parainfluenza virus has previously been shown to be an effective antigen delivery vector in humans. Notably and most importantly, following extensive testing in non-human primates, the attenuated BPI3V was shown to be well tolerated, infectious, immunogenic, and stable in infants and children. The vector is well suited for mucosal immunization using a nasal atomizer, but it can also be delivered parenterally.

Central
Nervous System (CNS) Pipeline

TNX-102 SL
(cyclobenzaprine HCl sublingual tablet): small molecule for the management of
fibromyalgia (FM)

  • Enrollment continues in the RESILIENT study, a double-blind, randomized, placebo-controlled, potentially pivotal Phase 3 study of TNX-102 SL for the management of fibromyalgia. The two-arm trial is expected to enroll approximately 470 participants in the U.S. Results from a planned interim analysis are expected in the first quarter of 2023.

TNX-102 SL for
the treatment of Long COVID, also known as Post-Acute Sequelae of COVID-19
(PASC)

  • The Company continues to expect to start a Phase 2 clinical study with TNX-102 SL as a potential treatment for a subset of patients with Long COVID with multi-site pain in the third quarter of 2022.
  • As previously announced, the results of a retrospective observational database study of over 50,000 adult U.S. patients with Long COVID showed that over 40% of patients had fibromyalgia-like multi-site pain. These findings support the feasibility of the planned Phase 2 study which will enroll Long COVID patients with multi-site pain.

TNX-102 SL for
the treatment of Posttraumatic Stress Disorder (PTSD)

  • Tonix expects to begin enrolling a Phase 2 study of TNX-102 SL in police in Kenya in the third quarter of 2022.

TNX-1300
(recombinant double mutant cocaine esterase): biologic for life-threatening
cocaine intoxication

  • In August 2022, Tonix announced that it received a Cooperative Agreement grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support development of TNX-1300.
  • The Company expects to initiate a new Phase 2 clinical study of TNX-1300 for the treatment of cocaine intoxication in the fourth quarter of 2022, pending agreement with the U.S. Food and Drug Administration (FDA). The Phase 2 trial, which has the potential to be a pivotal study, is a single-blind, open-label, placebo-controlled, randomized study comparing the safety of a single 200 mg dose of TNX-1300 to standard of care alone in approximately 60 emergency department patients presenting with cocaine intoxication.
  • A positive Phase 2a study of volunteer cocaine users in a controlled laboratory setting has been previously completed. TNX-1300 has been granted Breakthrough Therapy designation by the FDA.

TNX-1900
(intranasal potentiated oxytocin): small peptide for migraine, craniofacial
pain, insulin resistance and related disorders, and obesity associated binge
eating disorder

  • Tonix announced that U.S. Patent 11,389,473 issued in July 2022. The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use” claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations. This patent, excluding possible patent term extensions, is expected to provide Tonix with U.S. market exclusivity until January 2036.
  • Tonix announced the publication of a paper, entitled “Impact of Magnesium on Oxytocin Receptor Function,” in the journal Pharmaceutics, that described results from a research team led by Professor David Yeomans. The paper includes data showing the enhancing effects of magnesium (Mg2+) on the activity of intranasal oxytocin in an animal model of craniofacial pain. The Mg2+ potentiated formulation of intranasal oxytocin is the basis for the Company’s TNX-1900 drug candidate in development to prevent migraine headaches in chronic migraineurs. Professor Yeomans was the scientific founder of Trigemina, Inc. from which Tonix acquired rights to the Mg2+potentiated oxytocin technology. The potential clinical significance of these observations is that the formulation of oxytocin plus Mg2+ in Tonix’s TNX-1900 has the potential to enhance oxytocin efficacy for pain as well as for other uses.
  • The Company expects to begin enrollment in a Phase 2 study of TNX-1900 for the prevention of migraine headache in chronic migraineurs the first half of 2023.

TNX-601 ER
(tianeptine hemioxalate extended-release tablets): small molecule for the
treatment of major depressive disorder (MDD), PTSD, and neurocognitive
dysfunction associated with corticosteroid use.

  • In July 2022, Tonix announced development of a new extended release formulation of TNX-601, for the treatment of MDD. Tonix expects to initiate a Phase 2 study of TNX-601 ER for the treatment of MDD in the first quarter of 2023, pending FDA clearance of its Investigational New Drug (IND) application.

Rare Disease
Pipeline

TNX-2900
(intranasal potentiated oxytocin): small peptide for the treatment of
Prader-Willi syndrome (PWS)

  • Tonix delivered a presentation titled, “TNX-2900 (Intranasal Oxytocin + Magnesium) in Development for the Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome” at the World Orphan Drug Congress USA in July 2022.
  • TNX-2900 has received Orphan Drug designation from the FDA for the treatment of PWS.

Immunology
Pipeline

TNX-1500
(anti-CD40L monoclonal antibody): third generation monoclonal antibody for
prophylaxis of organ transplant rejection and treatment of autoimmune
disorders.

      *All of
Tonix’s product candidates are investigational new drugs or biologics and have
not been approved for any indication.

Recent
Highlights—Facilities and Corporate

  • In July 2022, Tonix announced the appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development. In this role, Dr. Bavari will be responsible for leading Tonix’s development of its growing infectious disease pipeline and will serve as a key member of the Company’s executive leadership team.
  • In June 2022, Tonix held a ribbon-cutting ceremony for its Advanced Development Center (ADC) located in the New Bedford Business Park in North Dartmouth, Massachusetts. The new facility is designed for accelerated research, development and analytical capabilities, as well as the production of clinical trial quality vaccines for infectious diseases, including monkeypox, smallpox and COVID-19 as well as other infectious diseases for pandemic preparedness. The ADC is open and expected to soon perform process development and clinical trial manufacturing of live-virus vaccines.

Recent
Highlights–Financial

As of June 30, 2022, Tonix had $145.5 million of cash and cash equivalents, compared to $178.7 million as of December 31, 2021. In June 2022, Tonix issued 2,500,000 shares of Series A convertible redeemable preferred stock and 500,000 shares of Series B convertible redeemable preferred stock to certain institutional investors in a private placement for gross proceeds of $28.5 million. The Company expects to use the proceeds to redeem the preferred stock.

Cash used in operations was approximately $21.2 million for the three months ended June 30, 2022, compared to $19.1 million for the same period in 2021. Capital expenditures were approximately $14.4 million for the three months ending June 30, 2022 compared to $1.4 million for the same period in 2021. The increase was primarily due to the continued buildout of the ADC in North Dartmouth, Mass.

Second Quarter 2022 Financial Results

Research and development (R&D) expenses for the three months ended June 30, 2022 were $16.6 million, compared to $18.1 million for the same period in 2021. The decrease is predominately due to decreased non-clinical expenses, offset by an increase in employee-related expenses. We continue to expect R&D expenses to increase during 2022 as we move our clinical development programs forward and invest in our development pipeline.

General and administrative (G&A) expenses for the three months ended June 30, 2022 were $6.8 million, compared to $5.4 million for the same period in 2021. The increase is primarily due to employee-related expenses.

Net loss available to common stockholders was $27.4 million, or $1.22 per share, basic and diluted, for the three months ended June 30, 2022, compared to net loss of $23.6 million, or $2.25 per share, basic and diluted, for the same period in 2021. The basic and diluted weighted average common shares outstanding for the three months ended June 30, 2022 was 22,404,371, compared to 10,483,112 shares for the same period in 2021.

About Tonix
Pharmaceuticals Holding Corp.
*

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the third quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that is Phase 2 ready and has been granted Breakthrough Therapy designation by the FDA. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the first half of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the first half of 2023. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. TNX-801, Tonix’s vaccine in development to prevent smallpox and monkeypox, also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases. A Phase 1 study of TNX-801 is expected to be initiated in Kenya in the first half of 2023. Tonix’s lead vaccine candidate for COVID-19 is TNX-1850, a live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform. A Phase 1 study of the COVID-19 vaccine is expected to be initiated in the second half of 2023.

*All of Tonix’s product candidates are investigational
new drugs or biologics and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward
Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.


TONIX PHARMACEUTICALS HOLDING
CORP.

CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS

(In
Thousands, Except Share and Per Share Amounts)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

COSTS AND EXPENSES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

16,579

 

 

$

18,133

 

 

$

35,001

 

 

$

33,460

 

General and administrative

 

 

6,757

 

 

 

5,429

 

 

 

14,771

 

 

 

10,838

 

 

 

 

23,336

 

 

 

23,562

 

 

 

49,772

 

 

 

44,298

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Loss

 

 

(23,336

)

 

 

(23.562

)

 

 

(49,772

)

 

 

(44,298

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest and other income, net

 

 

196

 

 

 

9

 

 

 

215

 

 

 

92

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(23,140

)

 

 

(23,553

)

 

 

(49,557

)

 

 

(44,206

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock deemed dividend

 

 

4,255

 

 

 

 

 

 

4,255

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss available to common stockholders

 

$

(27,395

)

 

$

(23,553

)

 

$

(53,812

)

 

$

(44,206

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share, basic and diluted

 

$

(1.22

)

 

$

(2.25

)

 

$

(2.76

)

 

$

(4.49

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding, basic and diluted

 

 

22,404,371

 

 

 

10,483,112

 

 

 

19,462,280

 

 

 

9,843,309

 


TONIX PHARMACEUTICALS HOLDING
CORP.

CONDENSED
CONSOLIDATED BALANCE SHEETS

(In
Thousands)

(Unaudited)

 

June 30, 2022

 

December 31, 20211

Assets

 

 

Cash and cash equivalents

$

145,478

 

$

178,660

Restricted cash

 

31,500

 

—–

Prepaid expenses and other

 

14,769

 

 

10,389

Total current assets

 

191,747

 

 

189,049

Other non-current assets

 

84,418

 

 

51 ,851

Total assets

$

276,165

 

$

240,900

 

 

 

Liabilities and stockholders’ equity

 

 

Total liabilities

$

16,383

 

$

22,183

Temporary equity

 

31,500

 

 

Stockholders’ equity

 

228,282

 

 

218,717

Total liabilities and stockholders’ equity

$

276,165

 

$

240,900

1The condensed consolidated balance sheet for the year ended December 31, 2021 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Contacts

Jessica Morris
(corporate)

Tonix Pharmaceuticals
investor.relations@tonixpharma.com

(862) 799-8599

Olipriya Das,
Ph.D. (media)

Russo Partners
Olipriya.Das@russopartnersllc.com

(646) 942-5588

Peter Vozzo
(investors)

ICR Westwicke
peter.vozzo@westwicke.com

(443) 213-0505

 


Source: Tonix Pharmaceuticals Holding Corp.

Released
August 8, 2022


Release – Energy Fuels Announces Q2-2022 Results, Including Continued Robust Balance Sheet And Market-Leading U.S. Uranium And Rare Earth Positions

 


 


Energy Fuels Announces Q2-2022 Results, Including Continued Robust Balance Sheet And Market-Leading U.S. Uranium And Rare Earth Positions

Research, News, and Market Data on Energy Fuels

Webcast
on August 9, 2022

 

LAKEWOOD, Colo., Aug. 5, 2022 /CNW/ – 
Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) (“Energy Fuels” or the “Company”) today reported its financial results for the quarter ended June 30, 2022. The Company’s quarterly report on Form 10-Q has been filed with the U.S. Securities and Exchange Commission (“SEC“) and may be viewed on the Electronic Document Gathering and Retrieval System (“EDGAR“) at 
www.sec.gov/edgar.shtml, on the System for Electronic Document Analysis and Retrieval (“SEDAR“) at www.sedar.com, and on the Company’s website at www.energyfuels.com. Unless noted otherwise, all dollar amounts are in U.S. dollars.

Highlights:

  • At June 30, 2022, the Company had a robust balance sheet with $134.1 million of working capital, including $86.4 million of cash and cash equivalents, $11.8 million of marketable securities, $28.6 million of inventory, and no short term (or long term) debt. At current commodity prices, the Company’s product inventory has a value of $43.9 million.
  • During the quarter ended June 30, 2022, the Company incurred a net loss of $18.1 million, which included a non-cash mark-to-market decrease in the value of investments accounted for at fair value of $13.4 million.
  • During Q2-2022, the Company entered into three (3) long-term uranium sales contracts with U.S. nuclear utilities. Base quantities under these contracts total 3.0 million pounds with deliveries to occur during the 2023 – 2030 time period. If the buyers exercise all options, total delivery quantities could increase to as much as 4.2 million pounds. Annual quantities vary year-to-year, with lower delivery quantities in the early years, and higher quantities in the later years. Contract pricing has a fixed price component (fully indexed to inflation) and a spot market component, along with floor and ceiling prices (fully indexed to inflation). The Company expects to fulfill deliveries during the early years of these contracts from its significant existing produced inventories.
  • In June 2022, the U.S. Department of Energy (“DOE“) issued a Request for Proposals (“RFP“) to purchase uranium (“U3O8“) for the new U.S. Uranium Reserve (the “Reserve“). The DOE states that they expect to purchase up to 1 million pounds of U3O8 inventory from up to four (4) qualified U.S. uranium producers. The uranium must be physically located at Honeywell’s Metropolis Works conversion facility (the “U.S. Converter“). Energy Fuels believes it meets all qualifications to supply the Reserve, and the Company currently holds about 692,000 pounds of U3O8 at the U.S. Converter. The Company has submitted a bid to sell U3O8 to the Reserve, taking into consideration its long-term contract commitments and current and expected market conditions. There are no guarantees the DOE will purchase uranium from the Company under this RFP.
  • During the first half of 2022, the Company produced approximately 205 tonnes of mixed rare earth element (“REE“) carbonate (“RE Carbonate“), containing approximately 95 tonnes of total rare earth oxides (“TREO“). Energy Fuels’ RE Carbonate, which is roughly 32% – 34% NdPr, is the most advanced REE material being produced in the U.S. today.
  • In May 2022, the Company announced it had entered into agreements to acquire a 58 square mile rare earth land position in Brazil (the “Bahia Project“). The Bahia Project is a well-known heavy mineral sand (“HMS“) deposit that has the potential to feed the Company’s White Mesa Mill with REE and uranium-bearing monazite sand for decades. Due diligence is ongoing, and closing is currently expected to occur on or around August 31, 2022. After closing, the Company expects to conduct an extensive exploration program to better define the HMS and monazite resource, including comprehensive sonic drilling and geophysical mapping with the intent to complete an Initial Assessment under SK-1300 (U.S.) and a Preliminary Economic Assessment under NI 43-101 (Canada) during Q4-2022 or Q1-2023.
  • The Company is currently in active discussions with several additional sources of natural monazite sands around the world to significantly increase the supply of feed for its growing REE initiative.
  • The Company continues to make excellent progress toward installing full REE separation capabilities at the Mill to produce both “light” and “heavy” separated REE oxides in the coming years, subject to successful licensing, financing, and commissioning, and continued strong market conditions. The Company has hired Carester SAS (“Carester“), a global leader in producing separated REE oxides, to support these REE separation initiatives. The Company is also evaluating installing a smaller “light” separation circuit within the existing Mill facilities with the ability to produce up to 1,500 tonnes TREO and 375 tonnes of NdPr oxide per year in the next 18-24 months. Initial estimates indicate low capital and operating costs for this circuit until a larger facility in the order of 10,000 tonnes TREO can be permitted, constructed and commissioned.
  • During the first half of 2022, the Company sold approximately 575,000 pounds of the Company’s existing inventory of vanadium (“V2O5“) (as ferrovanadium, “FeV“), for an average weighted net price of $13.44 per pound of V2O5. Vanadium markets have dropped in recent weeks. Therefore, the Company has halted sales of its inventory which currently stands at approximately 1.05 million pounds of V2O5. However, the Company expects to resume sales when markets improve again. The Company is evaluating the potential to resume vanadium recovery at the Mill in the future as market conditions may warrant for future sale and to replace sold inventory, where its tailings pond solutions contain an estimated additional 1.0 to 3.0 million recoverable pounds of V2O5.
  • To bolster the Company’s management team during its current growth phase and expansion into the REE industry, Energy Fuels has hired John Uhrie as Chief Operating Officer (“COO“), effective August 1, 2022, and Tom Brock as Chief Financial Officer (“CFO“), effective August 8, 2022. Mr. David Frydenlund, the Company’s current CFO, General Counsel and Corporate Secretary, was appointed to the position of Executive Vice President, Chief Legal Officer and Corporate Secretary of the Company, effective August 8, 2022. Mr. Brock previously served as Vice President and Chief Accounting Officer for Extraction Oil and Gas Inc. and prior thereto as Vice President, Chief Accounting Officer and Corporate Controller for American Midstream Partners LP. Dr. Uhrie most recently served as Vice President for Metals, Exploration and Development for The Doe Run Company, a global leader in lead, zinc and copper production and prior thereto as President, Consulting Services of the Americas for RPM Global, as Manager of Process Metallurgy for Newmont Mining Corp., and as Manager, Metallurgy and Strategic Planning, Africa and Manager of Hydrometallurgical Operations for Freeport McMoRan Copper and Gold, Bagdad Operations. Both Mr. Brock and Dr. Uhrie bring significant experience in managing producing natural resource companies.

Mark S. Chalmers, Energy Fuels’ President and CEO, stated:

“Energy Fuels continues to make progress on all fronts of our uranium, rare earth, vanadium and medical isotope businesses. Uranium markets have been volatile but remain strong. We continue to believe the short and long-term fundamentals for uranium continue to point to higher pricing. We are extremely pleased to announce the execution of three long-term contracts with U.S. nuclear utilities. With up to 4.2 million pounds of uranium deliveries between 2023 and 2030, at attractive pricing and other terms, these contracts will help underpin Energy Fuels’ uranium business for many years to come. We are also beginning to perform the work needed to recommence production at one or more of our uranium mines. The Company’s substantial existing uranium inventories are expected to provide sufficient uranium for the early years of the contract deliveries. However, we expect to be in production at one or more of our uranium mines in the next two years. Our substantial inventories will also allow Energy Fuels the potential to offer significant quantities of uranium to the new U.S. Uranium Reserve. During the second half of 2022, we expect to shift back to processing stockpiled ores for uranium production, and we expect to produce 100,000 to 120,000 pounds of uranium in 2022.

“We sold some of our substantial vanadium inventories during the first half of 2022, as prices rose during the quarter. However, in recent weeks, vanadium prices have dropped back. Therefore, we stopped our sales. Nonetheless, during the first half of 2022, we sold about 575,000 pounds of V2O5, contained in ferrovanadium, at an average net price of $13.44 per pound V2O5. Our vanadium inventory was carried on our balance sheet at $6.09 per pound V2O5, so we have been able to capture some gross margin on these sales. Plus, we still have another 1.05 million pounds of V2O5 in inventory that we can sell into future market strength.

“Energy Fuels’ rare earth initiative continues to proceed extremely well, and we believe we are making more progress, faster, than any other U.S. company. Last year, we began production of a high-purity mixed rare earth carbonate that is ready for separation. No other company in the U.S. is commercially producing a product as advanced as Energy Fuels. In March 2022, we began the partial separation of lanthanum from our rare earth carbonate, using existing solvent extraction equipment at our White Mesa Mill. This is the first commercial-scale rare earth separation to occur in the U.S. in many years. As a result, we produced a very high-purity rare earth carbonate, with most of the lanthanum removed, that contains about 32% – 34% NdPr. We also performed pilot-scale rare earth separation in the Mill’s laboratory, where we produced about two kilograms of high-purity NdPr oxide per day. We expect to resume rare earth processing later in 2022, when we receive additional shipments of monazite sand from Chemours. It is early days, but with the outstanding achievements of our internal staff, complemented by our relationships with Neo Performance Materials (“Neo“) and Carester, we are confident that we will restore U.S. rare earth separation capabilities in the coming years.

“Finally, our medical isotope initiative is also advancing nicely. As previously announced, we are evaluating the recovery of radioisotopes from our existing uranium and rare earth process streams at the White Mesa Mill that could potentially be used in emerging targeted alpha therapy (“TAT“) cancer therapeutics. We look forward to providing more information on this initiative in the coming months.

“Lastly, I would like to welcome Tom Brock and John Uhrie to Energy Fuels’ management team. I believe Energy fuels is making the leap to large-scale production of uranium and rare earth elements in the coming years. Therefore, we are extremely pleased to add these two individuals to our management team, both of whom have extensive experience in managing operating natural resource companies.”

Webcast at 4:00 pm EDT on August 9, 2022:

Energy Fuels will be hosting a video webcast on August 9, 2022 at 4:00 pm EDT (2:00 pm MDT) to discuss its Q2-2022 financial results, the outlook for 2022, uranium, rare earths, vanadium, and medical isotopes. To join the webcast and access the presentation and viewer-controlled webcast slides, please click on the link below:

Webcast Link

If you would like to participate in the webcast and ask questions, please dial in to 1-888-664-6392 (toll free in the U.S. and Canada).

A link to a recorded version of the proceedings will be available on the Company’s website shortly after the webcast by calling 1-888-390-0541 (toll free in the U.S. and Canada) and by entering the code 536175#. The recording will be available until August 23, 2022.

Selected Summary Financial Information:

$000’s, except per share data

Six months ended
June 30, 2022

Six months ended
June 30, 2021

Results
of Operations:

Total revenues

$

9,404

$

809

Gross profit

3,093

809

Operating loss

(16,920)

(17,189)

Net loss attributable to the company

(32,783)

(21,692)

Basic and diluted net loss per common share

(0.21)

(0.15)

$000’s

As at
June 30, 2022

As at
December 31, 2021

Financial
Position:

Working capital

$

134,089

$

143,190

Property, plant and equipment, net

21,515

21,983

Mineral properties

83,539

83,539

Total assets

288,258

315,446

Total long-term liabilities

13,927

13,805

Financial Discussion:

At June 30, 2022, the Company had $134.1 million of working capital, including $98.1 million of cash and cash equivalents and marketable securities and $28.6 million of inventory, including approximately 692,000 pounds of uranium and 1.05 million pounds of high-purity vanadium, both in the form of immediately marketable product. The current spot price of U3O8, according to TradeTech, is $48.75 per pound, and the current mid-point spot price of V2O5, according to Metal Bulletin, is $8.00 per pound. Based on those spot prices, the Company’s uranium and vanadium inventories have a current market value of $33.7 million and $8.4 million, respectively, totaling $42.1 million. The Company also holds RE Carbonate inventory with a current value of $1.8 million, for total product inventory of $43.9 million at current commodity prices.

During the quarter ended June 30, 2022, the Company incurred a net loss of $18.1 million, compared to a net loss of $10.8 million for the second quarter of 2021, and a net loss of $32.8 million for the six months ended June 30, 2022 compared to a net loss of $21.7 million during the first six months of 2021. The increased net losses in 2022 are due primarily to a non-cash mark-to-market decrease in the value of investments accounted for at fair value of $13.4 million for the second quarter of 2022 and $16.8 million for the six months ended June 30, 2022. The Company has seen improvement in the value of these investments accounted for at fair value subsequent to quarter end.

Operations Update and Outlook for 2022:

Overview

The Company continues to believe that uranium supply and demand fundamentals point to higher sustained uranium prices in the future. In addition, Russia’s recent invasion of Ukraine and the recent entry into the uranium market by financial entities purchasing uranium on the spot market to hold for the long-term has the potential to result in higher sustained spot and term prices and, perhaps, induce utilities to enter into more long-term contracts with non-Russian producers like Energy Fuels to ensure security of supply and more certain pricing. Having recently secured three long-term uranium contracts with major U.S. utilities, the Company is beginning to perform the work needed to recommence production at one or more of its mines and in-situ recovery (“ISR“) facilities, starting as soon as 2023. Until such time when the Company has ramped back up to commercial uranium production, it can rely on its significant uranium inventories to fulfill its new contract requirements. The Company also continues to evaluate selling a portion of its inventories on the spot market in response to future upside price volatility, into the newly created U.S. Uranium Reserve Program, or for delivery into additional long-term supply contracts if procured. During the first half of 2022, the Company also began selling a portion of its vanadium inventory into then strengthening markets.

The Company will also continue to seek new sources of revenue, including through its emerging REE business, as well as new sources of Alternate Feed Materials and new fee processing opportunities at the Mill that can be processed without reliance on current uranium sales prices. The Company is also seeking new sources of natural monazite sands (in addition to the proposed acquisition of the Bahia Project) for its emerging REE business, is evaluating the potential to recover radioisotopes for use in the development of TAT medical isotopes for the treatment of cancer, and continues its support of U.S. governmental activities to assist the U.S. uranium mining industry, including the new U.S. Uranium Reserve Program and other efforts to restore domestic nuclear fuel capabilities.

Extraction and Recovery Activities Overview

During 2022, the Company plans to recover 100,000 to 120,000 pounds of uranium and approximately 650 to 1,000 tonnes of mixed RE Carbonate containing approximately 300 to 450 tonnes of TREO.

No vanadium production is currently planned during 2022, though the Company sold some of its existing vanadium inventory into recent strong markets and is evaluating the potential to recommence vanadium production in 2023 or later years as market conditions may warrant for future sale and to replace sold inventory.

The Company has secured three new long-term sales contracts with U.S. nuclear utilities and is continuing to strategically pursue additional uranium sales commitments with pricing expected to have both fixed and market-related components. The Company believes that recent price increases, volatility and focus on security of supply in light of Russia’s invasion of Ukraine have increased the potential for the Company to make uranium sales and procure additional term sales contracts with utilities at pricing that sustains production and covers corporate overhead. Therefore, existing inventories may increase from 692,000 pounds of U3O8 to 792,000 to 812,000 pounds of U3Oat year-end 2022 or may increase to a lesser extent, or be reduced, in the event the Company sells a portion of its inventory on the spot market, to the U.S. Uranium Reserve, or pursuant to term contracts in 2022.

ISR Activities

The Company expects to produce insignificant quantities of U3O8 in the year ending December 31, 2022 from Nichols Ranch and Alta Mesa. Until such time when market conditions improve sufficiently, suitable term sales contracts can be procured, or the U.S. Uranium Reserve Program is expanded, the Company expects to maintain the Nichols Ranch and Alta Mesa Projects on standby and defer development of further wellfields and header houses.

Conventional Activities

Conventional Extraction and Recovery Activities

During the six months ended June 30, 2022, the Mill did not package any material quantities of U3O8, focusing instead on developing its REE recovery business. During the six months ended June 30, 2022, the Mill produced approximately 205 tonnes of RE Carbonate, containing approximately 95 tonnes of TREO. The Mill recovered small quantities of uranium during the Quarter, which were retained in circuit. During 2022, the Company expects to recover 100,000 to 120,000 pounds of uranium at the Mill as finished product. The Company expects to recover approximately 650 to 1,000 tonnes of mixed RE Carbonate containing approximately 300 to 450 tonnes of TREO at the Mill during 2022. The Company expects to sell all or a portion of its mixed RE Carbonate to Neo or other global separation facilities and/or to stockpile it for future production of separated REE oxides at the Mill or elsewhere. The Company is in advanced discussions with several sources of natural monazite sands (in addition to the Bahia Project) to secure additional supplies of monazite sands, which if successful, would be expected to allow the Company to increase RE Carbonate production.

In addition to its 692,000 pounds of finished uranium inventories currently located at North American conversion facilities and at the Mill, the Company has approximately 300,000 pounds of U3O8 contained in stockpiled Alternate Feed Materials and other ore inventory at the Mill that can be recovered relatively quickly in the future, as general market conditions may warrant (totaling about 992,000 pounds of U3Oof total uranium inventory). The Company is also seeking to acquire additional ore inventory from third party mine cleanup activities that can be recovered relatively quickly in the future.

The Company currently holds 1.05 million pounds of V2O5 in inventory, and there remains an estimated 1.0 to 3.0 million pounds of additional solubilized recoverable V2O5 remaining in tailings solutions awaiting future recovery, as market conditions may warrant.

Conventional Standby, Permitting and Evaluation Activities

During the six months ended June 30, 2022, standby and environmental compliance activities continued at the fully permitted and substantially developed Pinyon Plain Project (uranium and, potentially, copper) and the fully permitted and developed La Sal Complex (uranium and vanadium). The Company plans to continue carrying out engineering, metallurgical testing, procurement and construction management activities at its Pinyon Plain Project. The timing of the Company’s plans to extract and process mineralized materials from these Projects will be based on sustained improvements in general market conditions, procurement of suitable sales contracts and/or the expansion of the U.S. Uranium Reserve Program.

The Company is selectively advancing certain permits at its other major conventional uranium projects, such as the Roca Honda Project, which is a large, high-grade conventional project in New Mexico. The Company is also continuing to maintain required permits at its conventional projects, including the Whirlwind Project, which came out of temporary cessation during the Quarter, and the Sheep Mountain project. In addition, the Company will continue to evaluate the Bullfrog Project. Expenditures for certain of these projects have been adjusted to coincide with expected dates of price recoveries based on the Company’s forecasts. All these projects serve as important pipeline assets for the Company’s future conventional production capabilities, as market conditions may warrant.

Uranium Sales

During the six months ended June 30, 2022, the Company entered into three uranium sale and purchase agreements with major U.S. utilities, constituting its first new long-term supply contracts since 2018. Having observed a marked uptick in interest from nuclear utilities seeking long-term uranium supply, the Company remains actively engaged in pursuing additional selective long-term uranium sales contracts. 

The Company submitted a bid to sell a portion of its existing uranium inventory into the U.S. Uranium Reserve at pricing that provides an appropriate rate of return to the Company. There are no guarantees that the U.S. government will buy all, or any, of the uranium the Company offers for sale.

Vanadium Sales

As a result of strengthening vanadium markets, during the six months ended June 30, 2022, the Company sold approximately 575,000 pounds of V2O5 (as FeV) at a gross weighted average price of $13.44 per pound of V
2O5. The Company expects to sell its remaining finished vanadium product when justified into the metallurgical industry, as well as other markets that demand a higher purity product, including the aerospace, chemical, and potentially the vanadium battery industries. The Company expects to sell to a diverse group of customers in order to maximize revenues and profits. The vanadium produced in the 2018/19 pond return campaign was a high-purity vanadium product of 99.6%-99.7% V2O5. The Company believes there may be opportunities to sell certain quantities of this high-purity material at a premium to reported spot prices. The Company may also retain vanadium product in inventory for future sale, depending on vanadium spot prices and general market conditions.

RE Carbonate Sales

The Company commenced its ramp-up to commercial production of a mixed RE Carbonate in March 2021 and has shipped all its RE Carbonate produced to-date to Neo’s Silmet facility in Estonia, where it is currently being fed into their separation process. All RE Carbonate produced at the Mill in 2022 is expected to be sold to Neo for separation at Silmet. Until such time as the Company expects to permit and construct its own separation circuits at the Mill, production in future years is expected to be sold to Neo for separation at Silmet and, potentially, to other REE separation facilities outside the U.S. To the extent not sold, the Company expects to stockpile mixed RE Carbonate at the Mill for future separation and other downstream REE processing at the Mill or elsewhere. During the quarter ended June 30, 2022, the Company sold approximately 18,000 kilograms of TREO at an average price of $25.35 per kilogram of TREO.

As the Company continues to ramp up its mixed RE Carbonate production and additional funds are spent on process enhancements, improving recoveries, product quality and other optimization, profits from this initiative are expected to be minimal until such time when monazite throughput rates are increased and optimized. However, even at the current throughput rates, the Company is recovering most of its direct costs of this growing initiative, with the other costs associated with ramping up production, process enhancements and evaluating future separation capabilities at the Mill being expensed as underutilized capacity production costs applicable to RE Carbonate and development expenditures. Throughout this process, the Company is gaining important knowledge, experience and technical information, all of which will be valuable for current and future mixed RE Carbonate production and expected future production of separated REE oxides and other advanced REE materials at the Mill. As discussed above, the Company is evaluating installing a full separation circuit at the Mill to produce both “light” and “heavy” separated REE oxides in the coming years, subject to successful licensing, financing, and commissioning and continued strong market conditions, and has hired Carester to support these REE separation initiatives.

About Energy Fuels: Energy Fuels is a leading
U.S.-based uranium mining company, supplying U
3O8 to
major nuclear utilities. The Company also produces vanadium from certain of its
projects, as market conditions warrant, and is ramping up to full
commercial-scale production of RE Carbonate. Its corporate offices are in Lakewood,
Colorado near Denver, and all its assets and employees are in the
United States. Energy Fuels holds three of America’s key uranium production
centers: the White Mesa Mill in Utah, the Nichols Ranch ISR Project
in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill
is the only conventional uranium mill operating in the U.S. today, has a
licensed capacity of over 8 million pounds of U
3O8 per
year, and has the ability to produce vanadium when market conditions warrant,
as well as RE Carbonate from various uranium-bearing ores. The Nichols Ranch
ISR Project is currently on standby and has a licensed capacity of 2 million
pounds of U
3O8 per
year. The Alta Mesa ISR Project is also currently on standby and has a
licensed capacity of 1.5 million pounds of U
3Oper
year. In addition to the above production facilities, Energy Fuels also has one
of the largest S-K 1300 and NI 43-101 compliant uranium resource portfolios in
the U.S. and several uranium and uranium/vanadium mining projects on standby
and in various stages of permitting and development. The primary trading market
for Energy Fuels’ common shares is the NYSE American under the trading symbol
“UUUU,” and the Company’s common shares are also listed on the
Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’
website is www.energyfuels.com.

Cautionary Note Regarding Forward-Looking Statements: This
news release contains certain “Forward Looking Information” and
“Forward Looking Statements” within the meaning of applicable United
States and Canadian securities legislation, which may include, but are not
limited to, statements with respect to: production and sales forecasts; costs
of production; any expectation that the Company will be awarded any sales under
the U.S. Uranium Reserve; scalability, and the Company’s ability and readiness
to re-start, expand or deploy any of its existing projects or capacity to
respond to any improvements in uranium market conditions or in response to the
Uranium Reserve; any expectation as to future uranium, vanadium, RE Carbonate
or REE market fundamentals or sales; any expectation as to recommencement of
production at any of the Company’s uranium mines or the timing thereof; any
expectation regarding any remaining dissolved vanadium in the Mill’s tailings
facility solutions or the ability of the Company to recover any such vanadium
at acceptable costs or at all; any expectation as to the ability of the Company
to secure any new sources of Alternate Feed Materials or other processing
opportunities at the Mill; any expectation as to timelines for the permitting
and development of projects; any expectation as to longer term fundamentals in
the market and price projections; any expectation as to the implications of the
current Russian invasion of Ukraine on uranium, vanadium or other
commodity markets; any expectation that the Company will maintain its position
as a leading uranium company in the United States; any expectation
with respect to timelines to production; any expectation that the Mill
will be successful in producing RE Carbonate on a full-scale commercial basis;
any expectation that Neo will be successful in separating the Mill’s RE
Carbonate on a commercial basis; any expectation that Energy Fuels will be
successful in developing U.S. separation, or other value-added U.S. REE
production capabilities at the Mill, or otherwise, including the timing of any
such initiatives and the expected production capacity or capital and operating
costs associated with any such production capabilities; any expectation that
the Company will restore U.S. rare earth separation capabilities in the coming
years; any expectation with respect to the future demand for REEs; any
expectation with respect to the quantities of monazite sands to be acquired by
Energy Fuels, the quantities of RE Carbonate to be produced by the Mill or the
quantities of contained TREO in the Mill’s RE Carbonate; any expectation that
any additional supplies of monazite sands will result in sufficient throughput
at the Mill to reduce underutilized capacity production costs and allow the
Company to realize its expected margins on a continuous basis; any expectation
that the Company will close the acquisition of the Bahia Project as scheduled
or at all; any expectation that the Bahia Project has the potential to feed the
Mill with REE and uranium-bearing monazite sand for decades; any expectation
that the Company will complete comprehensive sonic drilling and geophysical
mapping at the Bahia Project or complete an Initial Assessment under SK-1300
(U.S.) and a Preliminary Economic Assessment under NI 43-101 (Canada) during
Q4-2022 or Q1-2023, or otherwise; any expectation that the Company’s evaluation
of thorium and radium recovery at the Mill will be successful; any expectation
that the potential recovery of medical isotopes from any thorium and radium
recovered at the Mill will be feasible; any expectation that any thorium,
radium and other isotopes can be recovered at the Mill and sold on a commercial
basis; any expectation as to the quantities to be delivered under existing
uranium sales contracts, or that such contracts may help underpin the Company’s
uranium business for many years to come; any expectation that the Company will
be successful in completing any additional contracts for the sale of uranium to
U.S. utilities; any expectation that any existing or potential future uranium
sales contracts will be at prices and quantities that provide an appropriate
rate of return or sustain production and cover corporate overhead; any
expectation that the value of the Company’s investments accounted for at fair
value may improve in future periods; and any expectation that the Company will
generate net income in future periods. Generally, these forward-looking
statements can be identified by the use of forward-looking terminology such as
“plans,” “expects,” “does not expect,” “is
expected,” “is likely,” “budgets,” “scheduled,”
“estimates,” “forecasts,” “intends,”
“anticipates,” “does not anticipate,” or
“believes,” or variations of such words and phrases, or state that
certain actions, events or results “may,” “could,”
“would,” “might” or “will be taken,”
“occur,” “be achieved” or “have the potential
to.” All statements, other than statements of historical fact, herein are
considered to be forward-looking statements. Forward-looking statements involve
known and unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the Company to be materially different
from any future results, performance or achievements express or implied by the
forward-looking statements. Factors that could cause actual results to differ
materially from those anticipated in these forward-looking statements include
risks associated with: commodity prices and price fluctuations; processing and
mining difficulties, upsets and delays; permitting and licensing requirements
and delays; changes to regulatory requirements; legal challenges; the
availability of sources of Alternate Feed Materials and other feed sources for
the Mill; competition from other producers; public opinion; government and
political actions; available supplies of monazite sands; the ability of the
Mill to produce RE Carbonate to meet commercial specifications on a commercial
scale at acceptable costs; the ability of Neo to separate the RE Carbonate
produced by the Mill to meet commercial specifications on a commercial scale at
acceptable costs; market factors, including future demand for REEs; the ability
of the Mill to be able to separate radium or other radioisotopes at reasonable
costs or at all; market prices and demand for medical isotopes; and the other
factors described under the caption “Risk Factors” in the Company’s
most recently filed Annual Report on Form 10-K, which is available for review
on EDGAR at www.sec.gov/edgar.shtml,
on SEDAR at www.sedar.com, and on
the Company’s website at www.energyfuels.com.
Forward-looking statements contained herein are made as of the date of this
news release, and the Company disclaims, other than as required by law, any
obligation to update any forward-looking statements whether as a result of new
information, results, future events, circumstances, or if management’s
estimates or opinions should change, or otherwise. There can be no assurance
that forward-looking statements will prove to be accurate, as actual results
and future events could differ materially from those anticipated in such
statements. Accordingly, the reader is cautioned not to place undue reliance on
forward-looking statements. The Company assumes no obligation to update the
information in this communication, except as otherwise required by law.

SOURCE Energy Fuels Inc.


Eagle Bulk Shipping (EGLE) – Eagle Bulk Shipping reports strong 2022-2Q results

Monday, August 08, 2022

Eagle Bulk Shipping (EGLE)
Eagle Bulk Shipping reports strong 2022-2Q results

Eagle Bulk Shipping Inc. (“Eagle”) is a US-based drybulk owner-operator focused on the Supramax/Ultramax mid-size asset class, which ranges from 50,000 and 65,000 deadweight tons in size; these vessels are equipped with onboard cranes allowing for the self-loading and unloading of cargoes, a feature which distinguishes them from the larger classes of drybulk vessels and provides for greatly enhanced flexibility and versatility- both with respect to cargo diversity and port accessibility. The Company transports a broad range of major and minor bulk cargoes around the world, including coal, grain, ore, pet coke, cement, and fertilizer. Eagle operates out of three offices, Stamford (headquarters), Singapore, and Hamburg, and performs all aspects of vessel management in-house including: commercial, operational, technical, and strategic.

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Results were up sharply versus last year and slightly above our forecast. Net revenues were $198.7m in the most recent quarter, up 53% versus last year and in line with our $205.0m estimate. Improved sales reflect higher TCE shipping rates ($30,207 vs. $21,580) and more operating days (5,707 vs. 4,778) due to more owned and chartered-in vessels (60 vs. 55). Favorable sales led to a jump in adjusted EBITDA (which excludes hedges) to $102.6m from $6.6m surpassing our $93.4m estimate. The EBITDA surprise was due to lower-than-expected voyage expenses. Adjusted net income was $81.6m ($4.98/diluted share) versus our $73m. 

Charter rates have slipped but still remain above historical averages. Shipping rates declined in the second quarter as fighting in Ukraine and overall global economic concerns affected prices. Eagle has locked in 72% of its shipping rates for the third quarter as compared to an 83% rate in the second quarter leaving it a bit more exposed to spot prices. The fourth quarter is typically the highest-priced quarter due to North American grain shipments. Management believes the market for dry bulk shipping is also favorable with China opening up, Russian and Ukraine grain shipments resuming, and Brazil iron ore supply growing. Management points out that new vessel construction is limited and new orders wouldn’t be completed until 2024….

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Coeur Mining (CDE) – Lowering Rating to Market Perform

Monday, August 08, 2022

Coeur Mining (CDE)
Lowering Rating to Market Perform

Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Second quarter 2022 results. Coeur reported a second quarter adjusted net loss of $13.1 million or $(0.05) per share, compared to a net loss of $840 thousand or $(0.00) per share, during the prior year period, and our net income estimate of $4.0 million, or $0.01 per share. The variance to our estimates was due in part to higher costs applicable to sales. Adjusted EBITDA amounted to $43.3 million. Second quarter sales included 2.5 million ounces of silver and 84,786 ounces of gold. Coeur reaffirmed full year production guidance and increased cost guidance to reflect inflationary pressures. We have lowered our full year 2022 EBITDA and EPS estimates to $151.8 million and $(0.12), respectively, and our 2023 estimates to $181.3 million and $0.11. Our estimates reflect higher costs and lower commodity prices.

Rochester advances. The POA 11 Rochester expansion project is advancing with completion expected in mid-2023. Coeur has committed approximately $523 million of the $600 million estimated project capital cost and has incurred $350 million of the total estimated project cost through June 30. Coeur expects to spend between $217 million and $257 million in 2022 and $131 million and $171 million in 2023. In our view, the project’s net present value of $348.1 million estimated in the most recent technical report dated December 2021 is at risk of erosion due to higher costs and lower silver prices. Recall the first technical report published in 2020 predicted a capital cost of $396.8 million, now north of $600 million, and a net present value of $633.8 million….

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

E.W. Scripps (SSP) – Strong Political Saves The Day

Monday, August 08, 2022

E.W. Scripps (SSP)
Strong Political Saves The Day

The E.W. Scripps Company (NASDAQ: SSP) is a diversified media company focused on creating a better-informed world. As one of the nation’s largest local TV broadcasters, Scripps serves communities with quality, objective local journalism and operates a portfolio of 61 stations in 41 markets. The Scripps Networks reach nearly every American through the national news outlets Court TV and Newsy and popular entertainment brands ION, Bounce, Defy TV, Grit, ION Mystery, Laff and TrueReal. Scripps is the nation’s largest holder of broadcast spectrum. Scripps runs an award-winning investigative reporting newsroom in Washington, D.C., and is the longtime steward of the Scripps National Spelling Bee. Founded in 1878, Scripps has held for decades to the motto, “Give light and the people will find their own way.”

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

In line Q2 results. The second quarter results were roughly in line with our estimates with revenues of $594.5 million versus our estimate of $603.0 million and adj. EBITDA of $140.2 million versus our estimate of $139.3 million. The biggest variance to our estimates was in the Scripps Networks business, which was adversely affected by weakened National and Direct Response advertising. 

Q3 guide is lower than our estimates, but not horrible. We are lowering our Q3 revenue estimate from $662.0 million to $638.5 million, which reflects 15% growth over the prior year comparable period. We are lowering our Q3 adj. EBITDA estimate from $207.5 million to $170.5 million. The revision reflects soft National advertising in its Networks business and weak Core advertising. The company should cycle to moderate expenses in its Network business in Q4. …

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Energy Fuels (UUUU) – More signs that production is getting closer to ramping up

Monday, August 08, 2022

Energy Fuels (UUUU)
More signs that production is getting closer to ramping up

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. Energy Fuels also produces vanadium from certain of its projects, as market conditions warrant, and is ramping up commercial-scale production of REE carbonate. Its corporate offices are in Lakewood, Colorado, near Denver, and all its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant, as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com.

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Energy Fuels reported 2022-2Q results in line with expectations, absent mark-to-market losses. The company reported a loss of $18.1 million or $0.11 per share. However, that included a $13.4 million negative mark to market of the value of investments. Absent that charge, adjusted net income would have been a loss of $4.7 million, or $0.03 per share, vs. our forecast for a loss of $8.6 million, or $0.06 per share.

Vanadium and Rare Earth Element (RRE) sales are modest but poised to expand. The company sold 575,000 lbs. of vanadium, almost twice our forecast at an average price of $13.44/lb. Pricing has dropped so the company has discontinued sales. UUUU sold 205 tonnes of RRE, in line with expectations and pricing. Energy Fuels continues to make strides towards assuring RRE supply and developing circuits to separate heavy and light RRE at its White Mesa facilities….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Great Lakes Dredge & Dock (GLDD) – Corrected Copy: Income Statement Model

Monday, August 08, 2022

Great Lakes Dredge & Dock (GLDD)
Corrected Copy: Income Statement Model

Great Lakes Dredge & Dock Corporation is the largest provider of dredging services in the United States. In addition, Great Lakes is fully engaged in expanding its core business into the rapidly developing offshore wind energy industry. The Company has a long history of performing significant international projects. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 131-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprised of approximately 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident-and Injury-Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Corrected Model. An incorrect Income Statement model was attached to our second quarter update entitled “When It Rains…” and published August 3, 2022. A corrected version is attached. The error involves our full year 2022 revenue and adjusted EBITDA. The correct numbers are $692.8 million and $89.5 million, respectively, compared to $751.4 million and $89.9 million, respectively, in the prior consolidated income statement. The quarterly information is correct. Throughout the report we reference the correct $692.8 million revenue number. In certain instances, we do reference the incorrect $89.9 million adjusted EBITDA number but the de minimis difference between the two figures does not impact our investment case or valuation of GLDD shares.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.